Skip to main content
OpenTrials

Clinical trial condition

Carcinoma in Situ

Explore clinical trials studying Carcinoma in Situ. Study availability and eligibility vary by location and protocol.

51 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma in Situ trial results

Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

NCT06833073

Conditions
Carcinoma, Carcinoma in Situ, Female Urogenital Diseases, +13 more
Locations
  • Michael G Oefelein Clinical Trials ( Site 0138) Bakersfield, California, United States
  • Genesis Research, LLC ( Site 0141) Los Alamitos, California, United States
  • USC Norris Comprehensive Cancer Center ( Site 0123) Los Angeles, California, United States
  • Genesis Healthcare-Torrance ( Site 0140) Torrance, California, United States
View all 89 locations
View Trial Details
Recruiting

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

NCT05951179

Conditions
Carcinoma, Carcinoma in Situ, Female Urogenital Diseases, +14 more
Locations
  • Urology Centers of Alabama Homewood, Alabama, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • East Valley Urology Center of Arizona Queen Creek, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
View all 71 locations
View Trial Details
Recruiting

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

NCT07480356

Conditions
Bladder (Urothelial, Transitional Cell) Cancer, Carcinoma, Carcinoma in Situ, +16 more
Locations
  • East Valley Urology Center of Arizona Queen Creek, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • Michael Oefelein Clinical Trials Bakersfield, California, United States
  • Renown Regional Medical Center St Louis, Missouri, United States
View Trial Details
Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722

Conditions
Carcinoma, Carcinoma in Situ, Female Urogenital Diseases, +15 more
Locations
  • The University of Alabama at Birmingham Clinical Research Unit (CRU) Birmingham, Alabama, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • Urological Associates of South Arizona Tucson, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
View all 102 locations
View Trial Details
Recruiting

Project: Every Child for Younger Patients With Cancer

NCT02402244

Conditions
Adrenal Gland Pheochromocytoma, Bone Marrow Diseases, Carcinoma, +59 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Kingman Regional Medical Center Kingman, Arizona, United States
View all 278 locations
View Trial Details
Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT07283835

Conditions
Carcinoma, Carcinoma in Situ, Female Urogenital Diseases, +15 more
Locations
  • Peking University First Hospital (First Clinical Medical School of Peking University) Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital Chongqing, Chongqing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
View all 14 locations
View Trial Details
Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029

Conditions
Bites and Stings, Bladder Cancer, Breast Diseases, +72 more
Locations
  • California Research Institute Los Angeles, California, United States
  • BRCR Global Tamarac, Florida, United States
  • Gabrail Cancer Center Research Canton, Ohio, United States
  • Ohio State University Columbus, Ohio, United States
View all 16 locations
View Trial Details

Related conditions